Substituent Q Is Monocyclic Patents (Class 564/90)
-
Patent number: 10730828Abstract: The disclosed subject matter provides N-hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.Type: GrantFiled: October 18, 2016Date of Patent: August 4, 2020Assignees: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: Vincent Jacob Kalish, Lisa Marie Frost, Frederick Arthur Brookfield, Stephen Martin Courtney, John P. Toscano
-
Patent number: 9617208Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.Type: GrantFiled: July 31, 2015Date of Patent: April 11, 2017Assignees: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Patent number: 9115064Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.Type: GrantFiled: March 11, 2014Date of Patent: August 25, 2015Assignees: The Johns Hopkins University, Cardioxyl Pharmaceuticals, Inc.Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Patent number: 9040587Abstract: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals.Type: GrantFiled: June 24, 2011Date of Patent: May 26, 2015Inventors: David J. Schneider, Charles A. Schneider
-
Patent number: 9000045Abstract: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity. the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.Type: GrantFiled: March 21, 2012Date of Patent: April 7, 2015Assignee: Japan Tobacco Inc.Inventors: Hisashi Shinkai, Kimiya Maeda, Hiroshi Okamoto
-
Patent number: 8962889Abstract: The invention relates to a method of producing optically active ?-aminoaldehyde compound (3) by reacting imine compound (1-1) or sulfone compound (1-2) with aldehyde compound (2) in the presence of an optically active pyrrolidine compound. wherein each symbol is as defined in the specification.Type: GrantFiled: October 9, 2011Date of Patent: February 24, 2015Assignee: Sumitomo Chemical Company, LimitedInventor: Yujiro Hayashi
-
Patent number: 8859814Abstract: Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.Type: GrantFiled: May 14, 2009Date of Patent: October 14, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Derek Cogan, Alexander Heim-Riether, Wang Mao, Craig Andrew Miller, Philip Dean Ramsden, Lana Louise Smith Keenan, Roger John Snow, Jiang-Ping Wu, Yu Yang
-
Patent number: 8859815Abstract: A diamine of formula (I) is described in which A is hydrogen or a saturated or unsaturated C1-C20 alkyl group or an aryl group; B is a substituted or unsubstituted C1-C20 alkyl, cycloalkyl, alkaryl, alkaryl or aryl group or an alkylamino group and at least one of X1, X2, Y1, Y2 or Z is a C1-C10 alkyl, cycloalkyl, alkaryl, aralkyl or alkoxy substituting group. The chiral diamine may be used to prepare catalysts suitable for use in transfer hydrogenation reactions.Type: GrantFiled: December 7, 2011Date of Patent: October 14, 2014Assignee: Bial-Portela & C.A., S.A.Inventors: Beatriz Dominguez, Antonio Zanotti-Gerosa, Gabriela Alexandra Grasa, Jonathan Alan Medlock
-
Publication number: 20140235636Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: John P. Toscano, Art Sutton, Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
-
Patent number: 8809584Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-substituted-N-phenylethylsulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.Type: GrantFiled: December 21, 2011Date of Patent: August 19, 2014Assignee: Institut Univ. de Ciencia i Tecnologia, S.A.Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
-
Patent number: 8772541Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.Type: GrantFiled: December 14, 2012Date of Patent: July 8, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Xiang-qun Xie, Peng Yang, Rentian Feng
-
Patent number: 8741960Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, A, W1, W2, and R?1 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.Type: GrantFiled: January 25, 2007Date of Patent: June 3, 2014Assignee: Synta Pharmaceuticals Corp.Inventors: Shoujun Chen, Lijun Sun, Yu Xie
-
Publication number: 20140087005Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.Type: ApplicationFiled: October 8, 2013Publication date: March 27, 2014Applicants: Fox Chase Cancer Center, The Trustees of the University of PennsylvaniaInventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
-
Patent number: 8674132Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.Type: GrantFiled: June 22, 2012Date of Patent: March 18, 2014Assignees: The Johns Hopkins University, Cardioxyl Pharmaceuticals, Inc.Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Publication number: 20130245018Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicant: PIMCO 2664 LIMITEDInventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
-
Patent number: 8524778Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds.Type: GrantFiled: March 20, 2008Date of Patent: September 3, 2013Assignee: PIMCO 2664 LimitedInventors: Iain Robert Greig, Robert Jurgen Van't Hof, Stuart Hamilton Ralston
-
Publication number: 20130211139Abstract: The invention relates to a method of producing optically active ?-aminoaldehyde compound (3) by reacting imine compound (1-1) or sulfone compound (1-2) with aldehyde compound (2) in the presence of an optically active pyrrolidine compound. wherein each symbol is as defined in the specification.Type: ApplicationFiled: October 19, 2011Publication date: August 15, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Yujiro Hayashi
-
Patent number: 8314148Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: May 11, 2012Date of Patent: November 20, 2012Assignee: Novartis AGInventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin Keaney, Ayako Honda
-
Patent number: 8232427Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: March 27, 2007Date of Patent: July 31, 2012Assignee: Novartis AGInventors: Thomas Leutert, Jonathan E Grob, Ruben Alberto Tommasi, Erin E. Pusateri, Ayako Honda
-
Patent number: 8227639Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.Type: GrantFiled: September 26, 2008Date of Patent: July 24, 2012Assignees: Cardioxyl Pharmaceuticals, The Johns Hopkins UniversityInventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Patent number: 8193389Abstract: The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3?, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).Type: GrantFiled: March 11, 2005Date of Patent: June 5, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Martin Neitzel, Jennifer Marugg
-
Patent number: 8030356Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.Type: GrantFiled: March 16, 2007Date of Patent: October 4, 2011Assignees: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Patent number: 8022250Abstract: 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.Type: GrantFiled: December 24, 2009Date of Patent: September 20, 2011Assignee: Chiesi Farmaceutici S.p.A.Inventors: Luca Raveglia, Ilaria Peretto, Stefano Radaelli, Bruno Pietro Imbimbo, Andrea Rizzi, Gino Villetti
-
Patent number: 8003823Abstract: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used halogen sulfonamide organic compound for these applications is Chloramine-T. This invention deals with the new use of discovered compositions of matter, halo active aromatic sulfonamide organic compounds and use of solutions of these compounds as, odor control agents. The odor control solutions may be buffered to a predetermined pH. The odor control compositions may further incorporate small percentages of low molecular weight alcohols and wetting agents.Type: GrantFiled: October 28, 2009Date of Patent: August 23, 2011Inventors: David J. Schneider, Charles A. Schneider
-
Publication number: 20110189125Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.Type: ApplicationFiled: March 18, 2011Publication date: August 4, 2011Applicants: Trustees of the University of Pennsylvania, Fox Chase Cancer CenterInventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
-
Publication number: 20110166342Abstract: A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.Type: ApplicationFiled: January 4, 2011Publication date: July 7, 2011Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi Muto, Taisaku Tanaka, Hiroshi Maruoka, Seiichi Imajo, Yoshiaki Tomimori
-
Patent number: 7968721Abstract: This invention relates to a process for preparing a selective androgen receptor modulator (SARM) compound represented by the structure of formula I: wherein X is O; and T, Z, Y, Q, R and R1 are defined herein. The process includes coupling between an amide of formula II and a phenol of formula III followed by a purification step consisting of precipitating the compound of formula (I) in a mixture of alcohol and water alone.Type: GrantFiled: January 12, 2004Date of Patent: June 28, 2011Assignee: University of Tennessee Research FoundationInventors: Duane D. Miller, Karen A. Veverka, Kiwon Chung
-
Publication number: 20110105324Abstract: What is described are compounds of the formula (I) in which the respective substituents have the meanings given in the description. The compounds of the formula (I) can be used as herbicides and plant growth regulators.Type: ApplicationFiled: April 11, 2009Publication date: May 5, 2011Applicant: BAYER CROPSCIENCE AGInventors: Christoph Hugh Rosinger, Dieter Feucht, Klaus-Helmut Mueller, Isolde Haeuser-Hahn, Jan Dittgen, Ernst Rudolf Gesing, Christian Waldraff
-
Publication number: 20100240708Abstract: Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a ?-secretase enzyme; or (ii) the production of ?-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R1, and R2 are described herein.Type: ApplicationFiled: March 17, 2010Publication date: September 23, 2010Inventors: Dalton King, Zhaoxing Meng, Ivar M. McDonald, Richard E. Olson, John E. Macor
-
Publication number: 20100184986Abstract: Organocatalysts, particularly proline sulfonamide organocatalysts, having a first general formula as follows are disclosed. Embodiments of a method for using these organocatalysts also are disclosed. The method comprises providing a disclosed organocatalyst, and performing a reaction, often an enantioselective or diastereoselective reaction, using the organocatalyst. Solely by way of example, disclosed catalysts can be used to perform aldol reactions, conjugate additions, Michael additions, Robinson annulations, Mannich reactions, ?-aminooxylations, ?-hydroxyaminations, ?-aminations and alkylation reactions. Certain of such reactions are intramolecular cyclizations used to form cyclic compounds, such as 5- or 6-membered rings, having one or more chiral centers. Disclosed organocatalysts generally are much more soluble in typical solvents used for organic synthesis than are known compounds.Type: ApplicationFiled: March 17, 2010Publication date: July 22, 2010Inventors: Rich Garrett Carter, Hua Yang
-
Publication number: 20100120725Abstract: Compounds of Formula I, wherein R1-R8 are defined herein are provided, together with pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these compounds for inhibiting beta amyloid production and for the prevention and treatment of Alzheimer's disease and Down's syndrome are also described.Type: ApplicationFiled: January 21, 2010Publication date: May 13, 2010Applicants: Wyeth LLC, ArQule, Inc.Inventors: Anthony Frank Kreft, Derek Cecil Cole, Kevin Roger Woller, Joseph Raymond Stock, Kristina Martha Kutterer, Dennis Martin Kubrak, Charles William Mann, William Jay Moore, David Scott Casebier
-
Patent number: 7704988Abstract: This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.Type: GrantFiled: October 4, 2006Date of Patent: April 27, 2010Assignee: Merck & Co., Inc.Inventors: Robert J. DeVita, Gregori J. Morriello, Peter Lin
-
Patent number: 7700654Abstract: A process for isolating N-butylbenzenesulfonamide (NBBS) from biological material, the chemical synthesis of benzenesulfonamide derivatives, the use of NBBS and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma, the production of medicaments for the treatment thereof, and the use of NBBS and benzenesulfonamide derivatives as a lead substance in the development of active substances for treating benign prostatic hyperplasia and/or prostate carcinoma are provided.Type: GrantFiled: January 28, 2006Date of Patent: April 20, 2010Assignee: LTS Lohmann Therapie-Systeme AGInventors: Hans-Rainer Hoffmann, Rudolf Matusch, Aria Baniahmad
-
Publication number: 20100063076Abstract: This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.Type: ApplicationFiled: July 20, 2009Publication date: March 11, 2010Inventor: Scott L. Harbeson
-
Publication number: 20090318511Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: ApplicationFiled: March 27, 2007Publication date: December 24, 2009Inventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin E. Pusateri, Ayako Honda
-
Patent number: 7629492Abstract: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used halogen sulfonamide organic compound for these applications is Chloramine-T. This invention deals with the new use of discovered compositions of matter, halo active aromatic sulfonamide organic compounds and use of solutions of these compounds as, odor control agents. The odor control solutions may be buffered to a predetermined pH. The odor control compositions may further incorporate small percentages of low molecular weight alcohols and wetting agents.Type: GrantFiled: August 31, 2005Date of Patent: December 8, 2009Assignee: Schneider Advanced Technologies, Inc.Inventors: David J. Schneider, Charles A. Schneider
-
Patent number: 7569325Abstract: A photoresist monomer having a sulfonyl group, a polymer thereof and a photoresist composition containing the same are disclosed. The photoresist monomer is represented by following Formula. wherein, R* is a hydrogen atom or a methyl group, R1 and R2 are independently a C1˜C20 alkyl group, a C4˜C20 cycloalkyl group, a C6˜C20 aryl group or a C7˜C20 arylalkyl group, one of R1 and R2 may not exist, and R1 and R2 can be connected to form a ring.Type: GrantFiled: October 24, 2007Date of Patent: August 4, 2009Assignee: Dongjin Semichem Co., Ltd.Inventors: Jung-Youl Lee, Geun-Jong Yu, Sang-Jung Kim, Jae-Woo Lee, Deog-Bae Kim, Jae-Hyun Kim
-
Patent number: 7560592Abstract: A biocidal solution comprising aromatic N-halosulfonamide organic compounds and methods of using the biocidal solution are disclosed. The solution may further comprise a wetting agent, a low molecular weight alcohol, and buffering agents. The biocidal solution is used to arrest or kill unwanted organisms.Type: GrantFiled: August 18, 2006Date of Patent: July 14, 2009Assignee: SAT, Inc.Inventors: Charles A. Schneider, David J. Schneider
-
Publication number: 20090042929Abstract: There is provided a compound having Formula (I) R1-Z-R2 wherein R1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(?O)—CR3R4—X—(CR5R6)n-, wherein X is selected from NR7, S, O, S?O, and S(?O)2, wherein n is 0 or 1 and/or (c) R1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR8R9)p-NR10—S(?O)2—(CR11R12)q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR13R14)V—Y—(CR15R16)W— where Y is a heteroaryl group in which a bond in the heteroaryl ring is a iType: ApplicationFiled: March 23, 2006Publication date: February 12, 2009Applicant: Sterix LimitedInventors: Nigel Vicker, Xiangdong Su, Fabienne Pradaux, Michael John Reed, Barry Victor Lloyd Potter
-
Publication number: 20090005394Abstract: This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.Type: ApplicationFiled: January 11, 2008Publication date: January 1, 2009Inventor: Scott L. Harbeson
-
Patent number: 7465829Abstract: Halo active aromatic sulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to releaser active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used sulfonamide organic compound for these applications has been Chloramine T. This invention deals with nearly discovered halo active aromatic sulfonamide organic compounds and uses of these compounds as biocides, odor control agents, bovine teat cleaners, drugs for cultured fish, soap biocides, stain removal agents, and paint fungicides.Type: GrantFiled: February 18, 2003Date of Patent: December 16, 2008Assignee: Schneider Advanced Technologies, Inc.Inventors: Charles A Schneider, David J. Schneider
-
Patent number: 7435815Abstract: The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.Type: GrantFiled: May 31, 2007Date of Patent: October 14, 2008Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thierry Sifferlen, Thomas Weller
-
Publication number: 20080188659Abstract: This invention relates to methods for preparing halogenated amines.Type: ApplicationFiled: February 7, 2008Publication date: August 7, 2008Applicant: WyethInventors: Eddine Saiah, Huan-Qiu Li, Adrian Huang
-
Patent number: 7402598Abstract: The present invention relates to compounds of formula (I) as defined herein and salts or solvates thereof. Processes for preparing these compounds and pharmaceutical formulations containing them are also disclosed, as well as methods for the prophylaxis of treatment of a clinical condition using such compounds.Type: GrantFiled: July 24, 2003Date of Patent: July 22, 2008Assignee: Glaxo Group LimitedInventors: Keith Biggadike, Diane Mary Coe, Duncan Stuart Holmes, Brian Edgar Looker
-
Patent number: 7365196Abstract: A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.Type: GrantFiled: March 15, 2001Date of Patent: April 29, 2008Assignees: Merck Sharp & Dohme Ltd., Merck Frosst Canada & Co.Inventors: Patrice Charles Belanger, Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Edward Giles McIver, Alan John Nadin, Joseph George Neduvelil, Mark Steven Shearman, Adrian Leonard Smith, Timothy Jason Sparey, Graeme Irvine Stevenson, Martin Richard Teall
-
Patent number: 7323596Abstract: Compounds of formula (I) and (IA) have antibacterial or antiprotozoal activity: formula (1) formula (2) wherein: Z represents a radical of formula N(OH)CH(?O) or of formula C(?O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of formula N(OH)CH(?O), a hydroxy or amino group; R2 represents a radical of formula R10—(X)n-(ALK)m- wherein R10 represents hydrogen, or an optionally substituted c1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 ?alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent NH—, —O— or S— linkages, X represents NH—, —O— or S—, and m and n are independently 0 or 1; R3 represents hydrogen, C1-C6alkyl, or benzyl; and R4 is as defined in the specification.Type: GrantFiled: December 21, 2001Date of Patent: January 29, 2008Assignee: De Novo Pharmaceuticals Ltd.Inventors: Barry Porter, Paul Gane, Raymond Beckett, Kenneth Keavey, Jac Wijkmans, Lydia Saroglou
-
Patent number: 7321063Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: GrantFiled: February 24, 2004Date of Patent: January 22, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Roger D Tung, Mark A Murcko, Govinda R Bhisetti
-
Patent number: 7279578Abstract: The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.Type: GrantFiled: October 6, 2003Date of Patent: October 9, 2007Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thierry Sifferlen, Thomas Weller
-
Patent number: 7265130Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: December 30, 2003Date of Patent: September 4, 2007Assignee: Shionogi & Co., Ltd.Inventors: Yasuyuki Kawanishi, Hideyuki Takenaka, Kohji Hanasaki, Tetsuo Okada
-
Patent number: RE45314Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.Type: GrantFiled: October 3, 2013Date of Patent: December 30, 2014Assignees: The Johns Hopkins University, Cardioxyl Pharmaceuticals, Inc.Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish